Satoru Sasagawa
Overview
Explore the profile of Satoru Sasagawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sasagawa S, Kumai J, Wakamatsu T, Yui Y
Cancer Innov
. 2024 Jul;
3(2):e113.
PMID: 38946933
Background: Synovial sarcoma (SS) is an fusion gene-driven soft tissue sarcoma with mesenchymal characteristics, associated with a poor prognosis due to frequent metastasis to a distant organ, such as the...
2.
Kishi S, Mori S, Fujiwara-Tani R, Ogata R, Sasaki R, Ikemoto A, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003554
N-methyl-glycine (sarcosine) is known to promote metastatic potential in some cancers; however, its effects on bladder cancer are unclear. T24 cells derived from invasive cancer highly expressed GNMT, and S-adenosyl...
3.
Suzuki R, Wakamatsu T, Yoshida K, Matsuoka Y, Takami H, Nakai S, et al.
J Bone Oncol
. 2023 Jun;
41:100486.
PMID: 37260767
Malignant giant-cell tumors are extremely rare bone sarcomas that transform from conventional giant-cell tumors during long periods of treatment. Owing to their rarity, no further analysis of their molecular pathogenesis...
4.
Wakamatsu T, Ogawa H, Yoshida K, Matsuoka Y, Shizuma K, Imura Y, et al.
Front Oncol
. 2022 Jun;
12:893592.
PMID: 35677170
Background: Although biological resources are essential for basic and preclinical research in the oncological field, those of sarcoma are not sufficient for rapid development of the treatment. So far, some...
5.
Yui Y, Kumai J, Watanabe K, Wakamatsu T, Sasagawa S
Int J Cancer
. 2022 Mar;
151(5):739-751.
PMID: 35342929
The prognosis of patients with metastatic and recurrent osteosarcoma has not improved over the last 30 years because no effective treatment strategy has been established for lung metastases. Although molecular-targeted...
6.
Amari K, Sasagawa S, Imayoshi N, Toda Y, Hosogi S, Imamura T, et al.
Biochem Biophys Res Commun
. 2021 Dec;
588:147-153.
PMID: 34954522
Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity...
7.
Igarashi K, Yui Y, Watanabe K, Kumai J, Nishizawa Y, Miyaura C, et al.
BMC Cancer
. 2020 Aug;
20(1):802.
PMID: 32831047
Background: Clinical trials have been conducted to clarify the beneficial effects of VD3 (1α,25-dihydroxy vitamin D3, also known as calcitriol) treatment in prostate cancer. However, the molecular mechanisms underlying these...
8.
Watanabe K, Yui Y, Sasagawa S, Suzuki K, Kanamori M, Yasuda T, et al.
Oncotarget
. 2019 Feb;
10(2):161-174.
PMID: 30719211
Lung metastasis markedly reduces the prognosis of osteosarcoma. Moreover, there is no effective treatment for lung metastasis, and a new treatment strategy for the treatment of osteosarcoma lung metastasis is...
9.
Nakagawa H, Yui Y, Sasagawa S, Itoh K
J Neurooncol
. 2018 Apr;
139(1):43-50.
PMID: 29626288
Introduction: The prognosis for leptomeningeal metastasis (LM) remains extremely poor regardless of intrathecal chemotherapy with various drugs, and thus, new treatments are necessary. Butyrate is an endogenous 4-carbon saturated fatty...
10.
Nakagawa H, Sasagawa S, Itoh K
Oncol Lett
. 2018 Feb;
15(2):1495-1502.
PMID: 29434841
Sodium butyrate (SB), a short chain (C-4) saturated fatty acid, is present in the human bowel at increased concentrations (~2 mM) as a food metabolite. It has been demonstrated that...